ASCO 2026 | PROCEADE-PanTumor: anti-CEACAM5 ADC precemtabart tocentecan in PDAC
Zev Wainberg, MD, University of California, Los Angeles, CA, presents interim results from the PROCEADE-PanTumor trial (NCT06710132) of precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload, in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC). Early efficacy signals were encouraging in this heavily pretreated, largely irinotecan-exposed population. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think we have to acknowledge that there’s going to be other targets of importance in pancreatic cancer. I don’t think every patient should be limited just by what access they can get to RAS inhibitors, because we know that there are other targets beyond RAS that are of interest as well. And we’ve seen some of them at ASCO, PRMT5 inhibitors, and others...
I think we have to acknowledge that there’s going to be other targets of importance in pancreatic cancer. I don’t think every patient should be limited just by what access they can get to RAS inhibitors, because we know that there are other targets beyond RAS that are of interest as well. And we’ve seen some of them at ASCO, PRMT5 inhibitors, and others. And so we’re going to need other things besides RAS. And one of the interesting targets that we presented data on was CEACAM5. We’ve known that CEACAM5 is a target in colorectal cancer. There’s potent ADCs that are being developed. We tested it in pancreatic cancer, which about three-quarters of the patients do have a positive screening test. And what that means is they test positive with a high enough expression. And so that’s very important. And so we tested the drug in that group of patients and we had about a 18 to 20% response. It’s still immature in terms of their durability. And several of those patients had prior RAS inhibitor exposure. So in terms of novelty, I think it’s there in terms of putting it to the test and a larger group of patients that we still need to do. So this is a good clue that we should probably do that moving forward.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
